4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBCПодробнее

5-year monarchE results: abemaciclib + ET in high-risk EBCПодробнее

MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancerПодробнее

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BCПодробнее

Abemaciclib for HR+/HER2- advanced or metastatic breast cancerПодробнее

MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancerПодробнее

monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancerПодробнее

CDK4/6 for HR+ early breast cancer: monarchE resultsПодробнее

monarchE: adjuvant abemaciclib in HR+ breast cancerПодробнее

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim dataПодробнее

EMBER-2: preoperative imlunestrant for ER+/HER2- early stage breast cancerПодробнее

MonarchE TrialПодробнее

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

Erika Hamilton, MD, considers the significance of the monarchE study & the use of abemaciclibПодробнее

postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapyПодробнее

Prognosis of HR+HER2- eBreastCancer according to monarchE & NATALEE by Luca Arecco MD at #ESMO24Подробнее

Age-stratified findings from the monarchE trial of abemaciclib in breast cancerПодробнее

Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancerПодробнее

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancerПодробнее